Drug Approval | April 15, 2023
NS Pharma announces FDA clearance to initiate phase II study for an Exon 44 skipping candidate
Study efficacy measures will include the expression of dystrophin protein and motor function.
Study efficacy measures will include the expression of dystrophin protein and motor function.
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
KRIVIDA TRIVUS detects the specific virus causing a respiratory infection.
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
The company has reported total income of Rs. 701 crores during the period ended December 31, 2022
The company has reported total income of Rs. 781.40 crores during the period ended December 31, 2022
Theramex were searching for a platform to digitise the manual processes across their R&D landscape
The company has posted net profit of Rs. 475.94 crores for the period ended December 31, 2022
The company has reported total income of Rs. 1165.31 crores during the period ended December 31, 2022
Subscribe To Our Newsletter & Stay Updated
